Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 1, 2008, Pages 104-115

  Oltmanns, Matt H ^a   Samudre, Sandeep S ^a   Castillo, Ivan G ^b   Hosseini, Alireza ^a   Lichtman, Aron H ^b   Allen, Robert C ^b   Lattanzio Jr , Frank A ^a   Williams, Patricia B ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT; TIMOLOL; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SPECIFICITY; EYE IRRITATION; HEART RATE; INTRAOCULAR HYPERTENSION; MALE; NONHUMAN; OCULOPLETHYSMOGRAPHY; PALLIATIVE THERAPY; PLASMA HALF LIFE; PRESSURE MEASUREMENT; RAT; SLIT LAMP; SPRAGUE DAWLEY RAT; VEIN LIGATION;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BENZOXAZINES; BLOOD PRESSURE; BORNANES; CALCIUM CHANNEL BLOCKERS; HEART RATE; INTRAOCULAR PRESSURE; IRRITANTS; MALE; MORPHOLINES; NAPHTHALENES; OCULAR HYPERTENSION; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TIMOLOL;

EID: 38549120148     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0074     Document Type: Article

References (58)

1. Quigley, H.A., McKinnon, S.J., Zack, D.J., et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest. Ophthalmol. Vis. Sci. 41:3460-3466, 2000.
2. Quigley, H.A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 80:389-393, 1996.
3. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am. J. Ophthalmol. 130:429-440, 2000.
4. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The Collaborative Normal-Tension Glaucoma Study Group. Am. J. Ophthalmol. 126:487-497, 1998.
5. Hepler, R.S., and Frank, I.R. Marihuana smoking and intraocular pressure. JAMA 217:1392, 1971.
6. Colasanti, B.K., Powell, S.R., and Craig, C.R. Intraocular pressure, ocular toxicity, and neurotoxicity after administration of delta 9-tetrahydrocannabinol or cannabichromene. Exp. Eye Res. 38:63-71, 1984.
7. Colasanti, B.K., Craig, C.R., and Allara, R.D. Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Exp. Eye Res. 39:251-259, 1984.
8. Colasanti, B.K., Brown, R.E., and Craig, C.R. Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol. Gen. Pharmacol. 15:479-484, 1984.
9. Colasanti, B.K. A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol. J. Ocul. Pharmacol. 6:259-269, 1990.
10. Colasanti, B.K. Ocular hypotensive effect of marihuana cannabinoids: correlate of central action or separate phenomenon? J. Ocul. Pharmacol. Ther. 2:295-304, 1986.
11. Colasanti, B.K. Intraocular pressure, ocular toxicity, and neurotoxicity in response to 11-hydroxy-delta 9-tetrahydrocannabinol and 1-nantradol. J. Ocul. Pharmacol. Ther. 1:123-135, 1985.
12. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564, 1990.
13. Matsuda, L.A., Bonner, T.I., and Lolait, S.J. Localization of cannabinoid receptor mRNA in rat brain. J. Comp. Neurol. 327:535-550, 1993.
14. Munro, S., Thomas, K.L., and Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65, 1993.
15. Stamer, W.D., Golightly, S.F., Hosohata, Y., et al. Cannabinoid CB(1) receptor expression, activation, and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur. J. Pharmacol. 431:277-286, 2001.
16. Song, Z.H., and Slowey, C.A. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. J. Pharmacol. Exp. Ther. 292:136-139, 2000.
17. Porcella, A., Casellas, P., Gessa, G.L., et al. Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: Implications for the antiglaucoma properties of marihuana. Brain Res. Mol. Brain Res. 58:240-245, 1998.
18. Pate, D.W., Jarvinen, K., Urtti, A., et al. Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci. 63:2181-2188, 1998.
19. Zhong, L., Geng, L., Njie, Y., et al. CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. Invest. Ophthalmol. Vis. Sci. 46:1988-1992, 2005.
20. Rinaldi-Carmona, M., Barth, F., Heaulme, M., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:240-244, 1994.
21. Rinaldi-Carmona, M., Barth, F., Millan, J., et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284:644-650, 1998.
22. Samudre, S.S., Lattanzio, F.A., Jr., Williams, P.B., et al. Comparison of topical steroids for acute anterior uveitis. J. Ocul. Pharmacol. Ther. 20:533-547, 2004.
23. Quaranta, L., Gandolfo, F., Turano, R., et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest. Ophthalmol. Vis. Sci. 47:2917-2923, 2006.
24. Kobelt-Nguyen, G., Gerdtham, U.G., and Alm, A. Costs of treating primary open-angle glaucoma and ocular hypertension: A retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J. Glaucoma 7:95-104, 1998.
25. Uusitalo, R.J., and Palkama, A. Long-term evaluation of timolol. Acta. Ophthalmol. (Copenh.) 67:573-581, 1989.
26. Kass, M.A., Heuer, D.K., Higginbotham, E.J., et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:701-713; 2002, discussion 829-730.
27. Hodges, L.C., Reggio, P.H., and Green, K. Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits. Ophthalmic Res. 29:1-5, 1997.
28. Naveh, N., Weissman, C., Muchtar, S., et al. A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefe's Arch. Clin. Exp. Ophthalmol. 238:334-338, 2000.
29. Green, K.E., and Kearse, C.E. Ocular penetration of topical delta9-tetrahydrocannabinol from rabbit corneal or cul-de-sac application site. Curr. Eye Res. 21:566-570, 2000.
30. Kearse, E.C., and Green, K. Effect of vehicle upon in vitro transcorneal permeability and intracorneal content of delta9- tetrahydrocannabinol. Curr. Eye Res. 20:496-501, 2000.
31. Juntunen, J., Jarvinen, T., and Niemi, R. In-vitro corneal permeation of cannabinoids and their water-soluble phosphate ester prodrugs. J. Pharm. Pharmacol. 57:1153-1157, 2005.
32. Green, K., and Roth, M. Ocular effects of topical administration of delta9-tetrahydrocannabinol in man. Arch. Ophthalmol. 100:265-267, 1982.
33. Green, K., Wynn, H., and Bowman, K.A. A comparison of topical cannabinoids on intraocular pressure. Exp. Eye Res. 27:239-246, 1978.
34. Green, K., Bigger, J.F., Kim, K., et al. Cannabinoid penetration and chronic effects in the eye. Exp. Eye Res. 24:197-205, 1977.
35. Merritt, J.C., Perry, D.D., Russell, D.N., et al. Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J. Clin. Pharmacol. 21:467S-471S, 1981.
36. Muchtar, S., Almog, S., Torracca, M.T., et al. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: Effect on intraocular pressure in rabbits. Ophthalmic Res. 24:142-149, 1992.
37. Hosseini, A., Lattanzio, F.A., Williams, P.B., et al. Chronic topical administration of WIN-55-212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects. Exp. Eye Res. 82:753-759, 2006.
38. Ozturk, F., Ermis, S.S., Inan, U.U., et al. Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma. J. Ocul. Pharmacol. Ther. 21:68-74, 2005.
39. Tomita, G., Araie, M., Kitazawa, Y., et al. A three-year prospective, randomized, and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye 18:984-989, 2004.
40. Stewart, R.H., Kimbrough, R.L., and Ward, R.L. Betaxolol versus timolol. A six-month double-blind comparison. Arch. Ophthalmol. 104:46-48, 1986.
41. Schuman, J.S., Horwitz, B., Choplin, N.T., et al. A 1-year study of brimonidine twice-daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. The Chronic Brimonidine Study Group. Arch. Ophthalmol. 115:847-852, 1997.
42. Palkama, A., Uusitalo, H., Raij, K., et al. Comparison of the effects of adrenergic agonists and alpha-, beta 1-, beta 2-antagonists on the intraocular pressure and adenylate cyclase activity in the ciliary processes of the rabbit. Acta. Ophthalmol. (Copenh.) 63:9-15, 1985.
43. Mishima, H.K., Masuda, K., Kitazawa, Y., et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch. Ophthalmol. 114:929-932, 1996.
44. Hass, I., and Drance, S.M. Comparison between pilocarpine and timolol on diurnal pressures in open-angle glaucoma. Arch. Ophthalmol. 98:480-481, 1980.
45. Diestelhorst, M., Roters, S., and Krieglstein, G.K. The effect of latanoprost 0.005% once-daily versus 0.0015% twice-daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%. Graefe's Arch. Clin. Exp. Ophthalmol. 235:20-26, 1997.
46. Aung, T., Wong, H.T., Yip, C.C., et al. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: A preliminary study. Ophthalmology 107:1178-1183, 2000.
47. Alm, A., and Stjernschantz, J. Effects on intraocular pressure and side-effects of 0.005% latanoprost applied once-daily, evening or morning. A comparison with timolol. The Scandinavian Latanoprost Study Group. Ophthalmology 102:1743-1752, 1995.
48. Vasquez, C., and Lewis, D.L. The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J. Neurosci. 19:9271-9280, 1999.
49. Jarvinen, T., Pate, D.W., and Laine, K. Cannabinoids in the treatment of glaucoma. Pharmacol. Ther. 95:203-220, 2002.
50. Sugrue, M.F. New approaches to antiglaucoma therapy. J. Med. Chem. 40:2793-2809, 1997.
51. Boyd, S.T., and Fremming, B.A. Rimonabant - a selective CB1 antagonist. Ann. Pharmacother. 39:684-690, 2005.
52. Maurice, D.M. Drug delivery to the posterior segment from drops. Surv. Ophthalmol. 47(Suppl. 1):S41-S52, 2002.
53. Niederhoffer, N., and Szabo, B. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br. J. Pharmacol. 126:457-466, 1999.
54. Mordi, J.A., Lyle, W.M., and Mousa, G.Y. Does prior instillation of a topical anesthetic enhance the effect of tropicamide? Am. J. Optom. Physiol. Opt. 63:290-293, 1986.
55. Apt, L., and Henrick, A. Pupillary dilatation with single eyedrop mydriatic combinations. Am. J. Ophthalmol. 89:553-559, 1980.
56. Lyle, W.M., and Bobier, W.R. Effects of topical anesthetics on phenylephrine-induced mydriasis. Am. J. Optom. Physiol. Opt. 54:276-281, 1977.
57. Porcella, A., Maxia, C., Gessa, G.L., et al. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur. J. Neurosci. 13:409-412, 2001.
58. Gamell, L.S. Glaucoma Medical Therapy: Principles and Management. San Francisco, CA: American Academy of Ophthalmology, 1999:179-191.